"Gilead Invests $100M in Assembly Bio for Breakthrough Antiviral Therapies"
TL;DR Summary
Gilead has partnered with Assembly Bio to develop new antiviral treatments for herpesviruses, hepatitis B, and hepatitis D. Gilead will provide $100 million in funding, including cash and equity investment, and has the potential to offer up to $1.9 billion in milestone payments for successful clinical programs.
- Gilead spends $100M to partner with Assembly Bio on antivirals for hepatitis, herpes Endpoints News
- Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases Business Wire
- Gilead pays $100M for first dibs on all Assembly Bio assets, bolting antiviral engine to its R&D group FierceBiotech
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
64%
130 → 47 words
Want the full story? Read the original article
Read on Endpoints News